Metabolomics in Respiratory, Cardiovascular and Metabolic Disorders

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (1 December 2025) | Viewed by 1252

Special Issue Editor

Special Issue Information

Dear Colleagues,

Research and developments in biomarker discovery are central in modern health care for personalized and precision medicine. This is especially important in very prevalent chronic diseases that involve respiratory, cardiovascular, and endocrine–metabolic disorders. However, traditional research based on more conventional techniques and hypothesis-driven approaches has failed in this objective. Omics approaches, in contrast, are particularly relevant and useful tools to identify new molecular biomarkers to improve the screening and diagnosis, enable more precise phenotyping (i.e., heterogeneity of clinical presentations) and prognosis, and even suggest new potential therapeutic targets. In this context, genomics, transcriptomics, and proteomics have provided new insights in the last decade, contributing to advances in biomedicine. Metabolomics, in turn, represents an attractive strategy for profiling a wider panel of molecules closely related to pathophysiological conditions in patient fluid or tissue samples.

This Special Issue of Metabolites will be devoted to the development and use of metabolomics approaches at both translational and clinical levels. The specific topics will include metabolomics biomarker discovery in very prevalent disorders targeting the respiratory system (COPD, asthma, lung cancer, and interstitial fibrosis), the cardiovascular system (chronic heart failure, ischemic heart disease, cardiomyopathies), and the endocrine–metabolic framework (dyslipidemia, diabetes mellitus, hyperthyroidism, and hypothyroidism) in a personalized medicine context. Molecular understanding of metabolic pathophysiological contexts in all these disorders will undoubtedly help in their future clinical management.

Prof. Dr. Joaquim Gea
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • small molecules
  • mass spectrometry
  • NMR
  • personalized medicine
  • biomarkers
  • car-diovascular disorders
  • respiratory diseases
  • endocrine metabolic abnormalities

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2395 KB  
Article
Systemic Metabolomic Remodeling in Pressure Overload-Induced Heart Failure Indicates Modulation of a Gut–Liver–Heart Axis by the Adiponectin Receptor Agonist ALY688
by Yubin Lei, Benjie Li, Tori Gosse, Sungji Cho, Hye Kyoung Sung, Jiarui Chen and Gary Sweeney
Metabolites 2026, 16(1), 38; https://doi.org/10.3390/metabo16010038 - 1 Jan 2026
Viewed by 848
Abstract
Background/Objectives: Numerous studies have documented cardioprotective effects of adiponectin in animal models of cardiometabolic disease (CMD). Adiponectin receptor agonist ALY688 has demonstrated functional significance against pressure overload-induced cardiac remodeling events in a mouse model of heart failure with reduced ejection fraction (HFrEF), potentially [...] Read more.
Background/Objectives: Numerous studies have documented cardioprotective effects of adiponectin in animal models of cardiometabolic disease (CMD). Adiponectin receptor agonist ALY688 has demonstrated functional significance against pressure overload-induced cardiac remodeling events in a mouse model of heart failure with reduced ejection fraction (HFrEF), potentially through modulation of the systemic metabolome. However, the specific metabolites and their pathophysiological contribution to cardioprotection in cardiac hypertrophy or heart failure remain unclear. This study aimed to characterize systemic metabolic alterations across five tissues in HFrEF and determine how ALY688 modifies these pathways to mediate cardioprotection in the transverse aortic constriction (TAC) model. Methods: Targeted metabolic profiling was performed on heart, liver, muscle, epididymal white adipose tissue (eWAT), and serum collected five weeks post-surgery from wild-type male C57BL/6 mice. Mice underwent either Sham or TAC-induced left ventricular pressure overload, with or without daily subcutaneous ALY688 administration. Metabolites were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) and statistically analyzed at the tissue level. Results: Consistent with pathological cardiac remodeling, the comprehensive metabolomic analysis revealed that TAC induced widespread disruption of systemic metabolic homeostasis. ALY688 treatment significantly modified several key metabolite classes, including triglycerides (TGs) and glycosylceramides (HexCer). Notably, ALY688 also altered multiple gut-derived metabolites, including trimethylamine N-oxide (TMAO), 5-aminovaleric acid (5-AVA), and glycodeoxycholic acid (GDCA), highlighting a potential gut–liver–heart axis mediating its cardioprotective effects. Conclusions: These findings demonstrate that ALY688 mitigates TAC-induced metabolic dysregulation across multiple tissues. The identified metabolic signatures suggest that ALY688 exerts cardioprotective effects, at least in part, through restoration of systemic metabolic homeostasis and engagement of a gut–liver–heart metabolic axis. These results provide mechanistic insight into adiponectin receptor agonism and support further exploration of ALY688 as a potential therapeutic strategy for HFrEF. Full article
(This article belongs to the Special Issue Metabolomics in Respiratory, Cardiovascular and Metabolic Disorders)
Show Figures

Figure 1

Back to TopTop